Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xuesaitong Soft Capsule for coronary heart disease with blood stasis syndrome
ChiCTR1800014980Phase 4Recruiting
- Sponsor
- China Academy of Chinese Medical Sciences
- Start
- Mar 2018
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of panax notoginseng in coronary arteriosclerosis (2 arms), sponsored by China Academy of Chinese Medical Sciences. Primary endpoints: lncRNA, miRNA and 1 more. Started Mar 2018; status: recruiting.
02
Drugs
panax notoginseng
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR1800014980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800014980.